Search research articles
Contact Us
Filters
Showing results (11-20 of 44) with videos related to
Page
of 5
Sort By:
Clinical Kidney Journal
|
May 2, 2022
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study
Annette Bruchfeld, Hasan Magin, Patrick Nachman, et al.
Kidney360
|
December 26, 2024
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
Hong Zhang, Richard Lafayette, Bei Wang, et al.
Haematologica
|
May 30, 2013
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Shira Dinner, Wesley Witteles, Anosheh Afghahi, et al.
The American Journal of Cardiology
|
August 29, 2017
Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry)
Mirela Tuzovic, Yukari Kobayashi, Matthew Wheeler, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 10, 2017
Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure
Zubaid Rafique, Matthew R Weir, Macaulay Onuigbo, et al.
British Journal of Haematology
|
February 26, 2013
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Shira Dinner, Wesley Witteles, Ronald Witteles, et al.
Kidney International Reports
|
September 22, 2025
Efficacy of Acthar gel and Tacrolimus in DNA-JB9 Positive Fibrillary Glomerulopathy
James A Tumlin, Amber Podoll, Nelson Kopyt, et al.
Kidney International
|
August 25, 2024
Targeting APRIL in the treatment of glomerular diseases
Chee Kay Cheung, Jonathan Barratt, Richard Lafayette, et al.
Kidney International
|
October 21, 2022
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Jonathan Barratt, Richard Lafayette, Jens Kristensen, et al.
JACC. Heart Failure
|
October 14, 2019
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis
Christopher D Barrett, Katharine Dobos, Michaela Liedtke, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 44) with videos related to
Sort By:
Page
of 5
Clinical Kidney Journal
|
May 2, 2022
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study
Annette Bruchfeld, Hasan Magin, Patrick Nachman, et al.
Kidney360
|
December 26, 2024
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
Hong Zhang, Richard Lafayette, Bei Wang, et al.
Haematologica
|
May 30, 2013
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Shira Dinner, Wesley Witteles, Anosheh Afghahi, et al.
The American Journal of Cardiology
|
August 29, 2017
Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry)
Mirela Tuzovic, Yukari Kobayashi, Matthew Wheeler, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 10, 2017
Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure
Zubaid Rafique, Matthew R Weir, Macaulay Onuigbo, et al.
British Journal of Haematology
|
February 26, 2013
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Shira Dinner, Wesley Witteles, Ronald Witteles, et al.
Kidney International Reports
|
September 22, 2025
Efficacy of Acthar gel and Tacrolimus in DNA-JB9 Positive Fibrillary Glomerulopathy
James A Tumlin, Amber Podoll, Nelson Kopyt, et al.
Kidney International
|
August 25, 2024
Targeting APRIL in the treatment of glomerular diseases
Chee Kay Cheung, Jonathan Barratt, Richard Lafayette, et al.
Kidney International
|
October 21, 2022
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Jonathan Barratt, Richard Lafayette, Jens Kristensen, et al.
JACC. Heart Failure
|
October 14, 2019
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis
Christopher D Barrett, Katharine Dobos, Michaela Liedtke, et al.
Page
of 5